Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Danaher’s 10-K can exceed 250 pages, weaving life-sciences revenue, diagnostics margins, and dozens of recent acquisitions into dense footnotes. Finding how Cytiva lifted bioprocessing sales or when executives exercise options is time-consuming. Stock Titan decodes every Danaher SEC filing, turning complexity into clarity.
Our platform delivers AI-powered summaries that make Danaher SEC filings explained simply. Need the latest Danaher quarterly earnings report 10-Q filing? We tag segment performance so you can compare consumables growth quarter-over-quarter. Tracking governance? Get Danaher proxy statement executive compensation highlights in plain English. Material event on a new acquisition? See the Danaher 8-K material events explained the moment it posts to EDGAR. And because insider activity moves the stock, our alerts surface Danaher insider trading Form 4 transactions—including Danaher Form 4 insider transactions real-time—before the market digests them.
Investors use these insights to:
- Monitor R&D intensity versus peers with Danaher annual report 10-K simplified
- Spot integration costs from recent M&A using Danaher earnings report filing analysis
- Review Danaher executive stock transactions Form 4 ahead of earnings calls
- Understand environmental disclosures and DBS efficiency metrics without reading every footnote
Whether you’re understanding Danaher SEC documents with AI for strategic research or scanning for trading catalysts, Stock Titan provides real-time updates, expert context, and the confidence to act on every disclosure.
Danaher Corporation (DHR)
Danaher Corporation (DHR) reported new equity awards to its Senior Vice President and General Counsel, Jonathan Leiken. On November 15, 2025, he received 10,172 restricted stock units (RSUs)$0 per share. One third of these RSUs vest on each of the first, second, and third anniversaries of the grant date. On the same date, he was also granted an employee stock option to purchase 26,767 shares of common stock at an exercise price of $221.21 per share, with one third of the options becoming exercisable on each of the first three anniversaries of November 15, 2025.
Danaher Corporation (DHR)11/15/2025, Milosevich disposed of 35 shares of Danaher common stock at a price of $221.21 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on equity awards. Following this small transaction, he directly beneficially owns 4,420 shares of Danaher common stock. No derivative securities transactions were reported.
Danaher Corporation (DHR) reported an insider equity transaction by its Executive Vice President, Julie A. Sawyer Montgomery. On 11/15/2025, she disposed of 265 shares of Danaher common stock at a price of $221.21 per share, reported under transaction code F. Following this transaction, she beneficially owns 16,653 shares of Danaher common stock directly.
Danaher (DHR)
Danaher (DHR) reported an insider transaction by its EVP & Chief Financial Officer, Matthew McGrew. On 11/11/2025, he exercised 16,172 employee stock options at an exercise price of $62.85 per share and sold 16,172 common shares at a weighted average price of $214.6198.
Following these transactions, McGrew beneficially owns 20,062 common shares directly and 10,221.856 shares indirectly via a 401(k). The sale price reflected multiple trades between $214.580 and $214.810.
Danaher (DHR) insider transaction: Senior Vice President and General Counsel Brian W. Ellis reported option exercises and same‑day sales on 11/12/2025. He exercised employee stock options at $58.59 and sold the resulting shares in open market transactions at weighted average prices disclosed in footnotes.
Ellis exercised 7,109 options at $58.59, then sold 7,109 shares at $219.2131. He also exercised 14,667 options at $58.59, then sold 14,667 shares at $219.2321. Following these transactions, he beneficially owned 14,553 shares directly.
Footnotes state the sale prices were weighted averages within disclosed ranges, and describe the vesting schedules of the original option grants.
Danaher (DHR) director and officer Mitchell P. Rales reported open‑market sales totaling 437,000 shares of common stock on November 12, 2025 at weighted average prices of $217.64, $218.27, $219.43 and $220.15.
Following these transactions, he beneficially owns 553,228 shares directly. Indirect holdings include 912,654 shares through the Mitchell P. Rales Family Trust, 667 by a 401(k) plan, 3,256 in a trust for a daughter (plus another 3,256 in a second trust), and 25,671,000 shares through single‑member LLCs.
Danaher (DHR) disclosed insider activity by its SVP, Human Resources. On 11/10/2025, the officer exercised employee stock options for 4,176 shares at $88.24 (transaction code M), then sold 4,176 shares at a weighted average price of $210.4436 and 998 shares at $210.3118 (transaction code S).
The weighted average sale price reflects multiple trades between $210.4101 and $210.570. After these transactions, the officer beneficially owned 2,625 shares directly.
Danaher (DHR): A stockholder filed a Form 144 notice to sell up to 437,000 shares of common stock, with an aggregate market value of $91,743,780. The filing lists Monness, Crespi, Hardt & Co., Inc. as broker, an approximate sale date of 11/12/2025, and the NYSE as the exchange.
The seller previously acquired 1,900,000 shares on 06/11/2021 via a distribution from Capital Yield Corporation tied to a closely held corporation liquidation. In the past three months, Mitchell P. Rales reported a sale of 600,000 shares on 10/31/2025 for gross proceeds of $129,635,820. Shares outstanding were 706,349,563.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
